Favipiravir and hyperuricemia in patients with COVID-19-suggestions for future studies

Affiliations

¹ School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
² School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
³ School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom.
⁴ School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia.

Chia Siang Kow et al. Lancet Reg Health Southeast Asia. 2023.

. 2023 Aug 18:16:100267.

doi: 10.1016/j.lansea.2023.100267. eCollection 2023 Sep.

¹ School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
² School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
³ School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom.
⁴ School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia.

No abstract available

Conflict of interest statement

None.

1. Srisubat A., Thanasitthichai S., Kongsaengdao S., Maneeton N., Maneeton B., Akksilp S. Effectiveness of favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand. Lancet Reg Health Southeast Asia. 2023;11 doi: 10.1016/j.lansea.2023.100166. - DOI - PMC - PubMed
1. Kow C.S., Ramachandram D.S., Hasan S.S. Future of antivirals in COVID-19: the case of favipiravir. Int Immunopharmacol. 2022;103 doi: 10.1016/j.intimp.2021.108455. - DOI - PMC - PubMed
1. Shah P.L., Orton C.M., Grinsztejn B., et al. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. Lancet Respir Med. 2023;11(5):415–424. doi: 10.1016/S2213-2600(22)00412-X. - DOI - PMC - PubMed
1. Mishima E., Anzai N., Miyazaki M., Abe T. Uric acid elevation by favipiravir, an antiviral drug. Tohoku J Exp Med. 2020;251(2):87–90. doi: 10.1620/tjem.251.87. - DOI - PubMed
1. Li G., Wu X., Zhou C.L., et al. Uric acid as a prognostic factor and critical marker of COVID-19. Sci Rep. 2021;11(1) doi: 10.1038/s41598-021-96983-4. - DOI - PMC - PubMed